FMI
BPMC

F/M Investments’s Blueprint Medicines BPMC Stock Holding History

F/M Investments’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,276
Closed -$2.95M – 402
2025
Q1 		$2.95M Buy
33,276
+1,963
+6% +$191K 0.12% 177
2024
Q4 		$2.73M Buy
+31,313
New +$2.87M 0.1% 187

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

F/M Investments's BPMC Position: Q2 2025 in Review

F/M Investments sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 33,276 shares — an estimated $2.95M sold.

F/M Investments first reported a position in BPMC in Q4 2024 and held it in 2 quarters. The position peaked at $2.95M in Q1 2025. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • F/M Investments reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • F/M Investments sold 33,276 Blueprint Medicines shares in Q2 2025, an estimated $2.95M.
  • F/M Investments first reported a position in Blueprint Medicines in Q4 2024 and held it in 2 quarters.
  • F/M Investments's Blueprint Medicines position peaked at $2.95M in Q1 2025.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on F/M Investments's 13F filing for Q2 2025, filed 13 Aug 2025.